Accounts Receivable	6 Months Ended
Jun. 30, 2020
Receivables [Abstract]
Accounts Receivable	Accounts Receivable As of June 30, 2020 and December 31, 2019, the Company had accounts receivable of $6.3 million and $7.2 million respectively, which relates to royalty revenue from the sales of NARCAN®.

The entire disclosure for financing receivable.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196772

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2196816

Name:	us-gaap_FinancingReceivablesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration